Share Name Share Symbol Market Type Share ISIN Share Description
Midatech Pharma Plc LSE:MTPH London Ordinary Share GB00BKT14T00 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 9.75 9.50 10.00 9.75 9.75 9.75 0.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.6 -6.1 -7.0 - 10

Midatech Pharma PLC Extension of Janssen collaboration re Q-Sphera

17/01/2022 7:00am

UK Regulatory (RNS & others)

Midatech Pharma (LSE:MTPH)
Historical Stock Chart

From Nov 2021 to May 2022

Click Here for more Midatech Pharma Charts.


RNS Number : 5400Y

Midatech Pharma PLC

17 January 2022

17 January 2022

Midatech Pharma PLC

("Midatech" or the "Company")

Midatech announces extension of R&D collaboration with Janssen focused on

Q-Sphera technology

Midatech Pharma PLC (AIM: MTPH; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce the extension of its R&D collaboration with Janssen Pharmaceutica NV (Janssen) originally announced on 21 July 2020.

On 17 June 2021, the Company announced that, using its Q-Sphera technology, it had successfully encapsulated a proprietary Janssen experimental large molecule medicine and importantly preserved its functional integrity. The Company believes no other commercial or academic organisation has been able to successfully deliver any such experimental medicine over extended periods using methods capable of commercial scaling.

Building on this important discovery, the Company has extended its R&D collaboration with Janssen. Under the extended collaboration the Company will focus on maximizing drug loading and optimizing in vitro duration of release for this undisclosed Janssen experimental molecule using the Company's Q-Sphera technology.

Dmitry Zamoryakhin, Chief Scientific Officer of Midatech, said:

"We are excited about the potential of our Q-Sphera technology in the delivery of API via long acting injectables. We look forward to our continued collaboration with Janssen and the application of our technology specific to these APIs."

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014 (MAR).

  For more information, please contact: Midatech Pharma PLC 
    Stephen Stamp, CEO, CFO 
     Dmitry Zamoryakhin, CSO 
    Tel: +44 (0)29 2048 0180 
    Panmure Gordon (UK) Limited (Nominated Adviser and Joint 
    Freddy Crossley, Emma Earl (Corporate Finance) 
    Rupert Dearden (Corporate Broking) 
    Tel: +44 (0)20 7886 2500 
    Turner Pope Investments (TPI) Limited (Joint Broker) 
    Andrew Thacker / James Pope (Corporate Broking) 
     Tel: +44(0)20 3657 0050 
    IFC Advisory Limited (Financial PR and UK Investor Relations) 
    Tim Metcalfe / Graham Herring 
    Tel: +44 (0)20 3934 6630 
    Edison Group (US Investor Relations) 
     Maxwell Colbert 
     Tel: +1 (646) 653 7028 
              About Midatech Pharma PLC 
               Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: 
               MTP) is a drug delivery technology company focused on improving 
               the bio-delivery and bio-distribution of medicines. The Company 
               combines approved and development medications with its proprietary 
               and innovative drug delivery technologies to provide compelling 
               products that have the potential to powerfully impact the 
               lives of patients. 
               The Company has developed three in-house technology platforms, 
               each with its own unique mechanism to improve delivery of 
               medications to sites of disease. All of the Company's technologies 
               have successfully entered human use in the clinic, providing 
               important validation of the potential for each platform: 
                *    Q-Sphera(TM) platform: a disruptive micro-technology 
                     used for sustained release to prolong and control the 
                     release of therapeutics over an extended period of 
                     time (from weeks to months). 
                *    MidaSolve(TM) platform: an innovative nanotechnology 
                     used to dissolve insoluble drugs so that they can be 
                     administered in liquid form directly and locally into 
                *    MidaCore(TM) platform: a leading-edge nanotechnology 
                     used for targeting medications to sites of disease. 
               The platform nature of the technologies offers the potential 
               to develop multiple drug assets rather than being reliant 
               on a limited number of programmes. Midatech's technologies 
               are supported by 36 patent families including 120 granted 
               patents and an additional 70 patent applications. Midatech's 
               headquarters and R&D facility is in Cardiff, UK. For more 
               information please visit 
 Forward-Looking Statements 
  Certain statements in this press release may constitute "forward-looking 
  statements" within the meaning of legislation in the United 
  Kingdom and/or United States Private Securities Litigation 
  Reform Act. All statements contained in this press release 
  that do not relate to matters of historical fact should be 
  considered forward-looking statements, including, but not 
  limited to, , any payments that may be received, the success 
  of the research collaboration in developing novel products, 
  the strategic review and formal sale process. 
  Reference should be made to those documents that Midatech 
  shall file from time to time or announcements that may be 
  made by Midatech in accordance with the London Stock Exchange 
  AIM Rules for Companies ("AIM Rules"), the Disclosure and 
  Transparency Rules ("DTRs") and the rules and regulations 
  promulgated by the US Securities and Exchange Commission, 
  which contains and identifies other important factors that 
  could cause actual results to differ materially from those 
  contained in any projections or forward-looking statements. 
  These forward-looking statements speak only as of the date 
  of this announcement. All subsequent written and oral forward-looking 
  statements by or concerning Midatech are expressly qualified 
  in their entirety by the cautionary statements above. Except 
  as may be required under the AIM Rules or the DTRs or by relevant 
  law in the United Kingdom or the United States, Midatech does 
  not undertake any obligation to publicly update or revise 
  any forward-looking statements because of new information, 
  future events or otherwise arising. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

January 17, 2022 02:00 ET (07:00 GMT)

1 Year Midatech Pharma Chart

1 Year Midatech Pharma Chart

1 Month Midatech Pharma Chart

1 Month Midatech Pharma Chart
ADVFN Advertorial
Your Recent History
Midatech P..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20220520 14:42:37